BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Mar 15, 2026; 18(3): 112974
Published online Mar 15, 2026. doi: 10.4251/wjgo.v18.i3.112974
Endoscopic ultrasound-guided radiofrequency ablation: A game-changer in pancreatic cancer treatment
Chuan Tong, Yi-Qing Hui, Jun-Rong Wang
Chuan Tong, Yi-Qing Hui, School of Nursing, Jilin Medical University, Jilin 132000, Jilin Province, China
Jun-Rong Wang, Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, Changchun 130022, Jilin Province, China
Co-corresponding authors: Yi-Qing Hui and Jun-Rong Wang.
Author contributions: Tong C contributed to the writing and editing of the manuscript, Hui YQ and Wang JR contributed to the literature search, designed the overall concept and outline of the manuscript as co-corresponding authors; all authors have read and approve the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Corresponding author: Jun-Rong Wang, MD, PhD, Department of Gynaecology and Obstetrics, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130022, Jilin Province, China. junrongwang_2019@yeah.net
Received: August 11, 2025
Revised: November 25, 2025
Accepted: January 4, 2026
Published online: March 15, 2026
Processing time: 213 Days and 6.2 Hours
Core Tip

Core Tip: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is a promising minimally invasive treatment for pancreatic cancer, particularly in patients with unresectable or high-risk tumors. Recent technological advancements have improved procedural precision and safety, demonstrating high technical success rates and potential symptom palliation. When combined with chemotherapy, EUS-RFA may offer enhanced tumor control and survival benefits, though long-term clinical outcomes require further investigation. Additionally, the immunomodulatory effects of EUS-RFA may augment systemic anti-tumor immunity, offering a potential synergy with immunotherapies. However, larger randomized controlled trials and standardized protocols are needed to fully establish its role in the clinical management of pancreatic cancer.

Write to the Help Desk